Join to View Full Profile
151 Oyster Point Blvd., Suite 400South San Francisco, CA 94080
Dr. Chu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 2002 - 2004
Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 1999 - 2002
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pediatrics, 1996 - 1999
University of Rochester School of Medicine and DentistryClass of 1996
Certifications & Licensure
MD State Medical License 2003 - 2026
Publications & Presentations
PubMed
- 77 citationsMitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modelingIraj Hosseini, Kapil Gadkar, Eric Stefanich, Chi-Chung Li, Liping L. Sun
NPJ Systems Biology and Applications. 2020-08-28 - 173 citationsPolatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (...Franck Morschhauser, Ian W. Flinn, Ranjana H. Advani, Laurie H. Sehn, Catherine Diefenbach
The Lancet. Haematology. 2019-05-01 - 59 citationsPhase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.Ranjana H. Advani, Daniel Lebovic, Andy I. Chen, Mark Brunvand, Andre Goy
Clinical Cancer Research. 2017-03-01
Abstracts/Posters
- Safety and efficacy of FT596, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy in relapsed/refractory B-cell lymphomaBachanova V, Ghobadi A, Patel K, Park JH, Flinn IW, Shah P, Wong C, Bickers C, Szabo P, Wong L, Valamehr B, Atwal S, Chu YW, Elstrom R and Strati P, 2021 American Society of Hematology Annual Meeting, Atlanta, 11/5/2021
- Mosunetuzumab, a full-length bispecific CD20/CD3 antibody, displays clinical activity in relapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL): Interim safety and effi...Budde LE, Sehn LH, Assouline S, Flinn IW, Isfufi I, Yoon S-S, Kim W-S, Matasar MJ, Nastoupil LJ, Santiago R, Koh Y, Hernandez G, Li C-C, Kulkarni PR, McCall B, McClell..., 2018 American Society of Hematology Annual Meeting, Atlanta, GA USA, 11/29/2018
Press Mentions
CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical OfficerJuly 17th, 2023
Fate Therapeutics Appoints Wayne Chu, M.D. As Vice President, Clinical DevelopmentApril 18th, 2019
Research History
- Senior Research FellowExperimental Immunology Branch, Center for Cancer Research, National Cancer Institute, NIH2002 - 2004
Professional Memberships
- Member
- Member
- Society for Immunotherapy of Cancer - SITCMember
- American Society for Transplantation and Cellular Therapy - ASTCTMember
Industry Relationships
- Chief Medical Officer, CytomX TherapeuticsDisclosure: Full-time employee; stockholder2023 - Present
- Chief Medical Officer, Fate TherapeuticsClinical DevelopmentDisclosure: Full-time employee, stockholder2019 - Present
- Employee, Genentech/RocheGroup Medical Director, Product Development OncologyDisclosure: Full-time employee, Stockholder2009 - 2019
External Links
- LinkedInhttp://www.linkedin.com/in/yuwayechu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
